The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.

导出 OA

翻译打印收藏纠错

作者： Douglas J,Veale ^[1] ; Dennis,McGonagle ^[2] ; Iain B,McInnes ^[3] ; James G,Krueger ^[4] ; Christopher T,Ritchlin ^[5] ; Dirk,Elewaut ^[6] ; Keith S,Kanik ^[7] ; Thijs,Hendrikx ^[8] ; Gabriel,Berstein ^[9] ; Jennifer,Hodge ^[10] ; Jean-Baptiste,Telliez ^[11]

作者单位： The Centre for Arthritis and Rheumatic Diseases, St Vincent's University Hospital, Dublin, Ireland. ^[1] University College, Dublin, Ireland. ^[2] Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, UK. ^[3] NIHR Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds, UK. ^[4] Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK. ^[5] Laboratory of Investigative Dermatology, The Rockefeller University, New York, USA. ^[6] Allergy, Immunology & Rheumatology Division, University of Rochester Medical Center, Rochester, NY, USA. ^[7] Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center, Ghent University and Department of Rheumatology, Ghent University Hospital, Ghent, Belgium. ^[8] Pfizer Inc, Groton, CT, USA. ^[9] Pfizer Inc, Collegeville, PA, USA. ^[10] Pfizer Inc, Cambridge, MA, USA. ^[11] Pfizer Inc, New York, NY, USA. ^[12]